A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.
Epistemonikos ID: 57afd3ed8ddb88b78fd0a5cfc18d15183789ea04
First added on: May 04, 2024